Plain-English translation of NCT06215118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether and work well together to treat multiple myeloma—a cancer that starts in white blood cells—that has come back or stopped responding to prior treatments. The study has two parts: first, researchers will find a safe dose of this medication combination, and then they will test that dose in more patients to see if it truly helps.
Multiple myeloma patients whose disease returns or no longer responds to standard treatments have very limited options. This trial explores whether combining two newer medications might offer hope for patients who have already tried multiple other therapies.
You likely qualify if…
You likely don't qualify if…
You would receive as an injection under the skin and take as an oral pill by mouth for 21 days during each 28-day treatment cycle. You would continue this treatment as long as your disease responds and you tolerate the medications well. The study involves regular medical visits and monitoring to check how you respond and watch for side effects.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States